MOTIVATION LETTER The AI NATION Accelerator targets AI-first startups with scalable technology. My venture predicts drug resistance mutations from protein sequence alone, using ESM-2 protein language model delta-embeddings combined with ECFP4 drug fingerprints and a Random Forest classifier. On the Platinum benchmark of 553 mutations, the model achieves AUROC 0.804 plus or minus 0.025 under protein-grouped cross-validation. This beats the published SOTA for structure-dependent tools such as mCSM-lig, which reports AUROC approximately 0.70. More critically, the venture covers 100 percent of mutations in a given protein, whereas structure-limited tools cover roughly 18 percent because they require a resolved crystal structure. I am a pharmacist turned ML engineer. I hold a pharmacy degree and have built production machine learning systems. This combination means I understand both the biological mechanism of drug resistance and the statistical rigor required to validate a predictive model. The venture is pre-seed, proof-of-concept validated, and not yet incorporated. I am targeting incorporation in France, specifically Ile-de-France, to access the biopharma cluster around Paris-Saclay, Institut Pasteur, and partners such as Servier and Sanofi. The AI NATION Accelerator offers EUR 10,000 non-dilutive funding plus mentorship and ecosystem access. Germany hosts major pharma companies including Bayer and Merck. My technology applies directly to their drug development pipelines, particularly in oncology and antimicrobial resistance. The accelerator's focus on AI startups aligns with my technology stack, which is entirely compute-driven and requires no wet-lab infrastructure at this stage. The mentorship component is valuable because I am a solo founder and need guidance on go-to-market strategy in the EU regulatory environment. My roadmap is specific. I will fine-tune ESM-2 on the SKEMPI 3K mutation dataset to push AUROC above 0.70 on that benchmark. Then I will initiate a pilot with Servier at their Suresnes site. The target is annual recurring revenue from pharma licensing within 18 months of incorporation. The AI NATION Accelerator can accelerate this timeline by connecting me with German pharma partners and providing the compute credits needed for model retraining. I am applying because the venture is at the exact stage where non-dilutive capital and structured mentorship have the highest use. The EUR 10,000 will cover cloud compute for the SKEMPI fine-tuning run and legal costs for incorporation in France. I am ready to relocate for programme activities if required. SHORT ESSAY: INNOVATION AND TECHNOLOGICAL DIFFERENTIATION The venture's core innovation is predicting drug resistance mutations without requiring a protein crystal structure. Existing tools such as mCSM-lig, FoldX, and Rosetta depend on a 3D structure, which is unavailable for approximately 82 percent of clinically relevant mutations. My model uses ESM-2 protein language model embeddings to represent the protein sequence, then computes delta-embeddings between wild-type and mutant sequences. These are concatenated with ECFP4 drug fingerprints and fed into a Random Forest classifier. On the Platinum benchmark, which contains 553 mutations across diverse protein-drug pairs, the model achieves AUROC 0.804 with standard deviation 0.025 under protein-grouped cross-validation. This is a rigorous evaluation because it tests on proteins not seen during training. The published SOTA for structure-dependent tools on the same benchmark is approximately 0.70. On SKEMPI 2.0, a binding affinity benchmark, the model scores 0.634, which is the baseline I will improve by fine-tuning ESM-2 on the larger SKEMPI 3K dataset. The technology is entirely sequence-based. It can score any mutation for any protein-drug pair in under one second on a single GPU. This enables high-throughput screening of resistance profiles across entire proteomes, which is impossible with structure-dependent methods. The model is also interpretable: feature importance from the Random Forest identifies which embedding dimensions and fingerprint bits drive the prediction, allowing biologists to validate the mechanism. SHORT ESSAY: MARKET POTENTIAL AND SCALABILITY Drug resistance is a multi-billion dollar problem in oncology, antivirals, and antimicrobials. Every new molecular entity faces the risk of resistance emerging during clinical trials or post-market. Pharma companies currently rely on costly and slow experimental resistance profiling, or on structure-based computational tools that miss most mutations. My venture offers a faster, cheaper, and more thorough alternative. The addressable market is pharma R&D budgets for computational drug discovery, estimated at USD 4.5 billion globally and growing at 12 percent annually. The initial target is licensing the prediction tool to mid-size and large pharma companies for internal pipeline use. The business model is software-as-a-service with per-protein or per-mutation pricing, plus consulting fees for custom model fine-tuning on proprietary compound libraries. Scalability is inherent in the technology. Adding a new protein-drug pair requires only the protein sequence and the drug SMILES string. No wet-lab data generation is needed. The model can be deployed as an API, allowing pharma partners to integrate it into their existing computational workflows. The unit economics improve with each new partner because the model benefits from transfer learning across protein families. The venture will first target European pharma, specifically Servier, Sanofi, and German partners such as Bayer and Merck. After proof of revenue, expansion to US and Asian markets is planned. The AI NATION Accelerator's network in Germany is directly relevant to this strategy. SHORT ESSAY: FOUNDING TEAM AND FEASIBILITY I am the sole founder. I hold a pharmacy degree and have worked as a machine learning engineer building production models for two years. My pharmacy training gives me domain expertise in pharmacology, drug mechanisms, and resistance pathways. My ML engineering experience means I can build, deploy, and maintain the entire technology stack myself. I have already validated the proof-of-concept, achieving the AUROC 0.804 result on Platinum benchmark as a solo researcher. The project plan is feasible because the technology is compute-only and requires no wet-lab. The next milestone is fine-tuning ESM-2 on the SKEMPI 3K dataset, which requires approximately 500 GPU-hours and access to the dataset, which is publicly available. I have budgeted EUR 3,000 for cloud compute for this phase. The EUR 10,000 from AI NATION covers this and leaves EUR 7,000 for incorporation and legal fees in France. I have already initiated discussions with SEMIA and Quest for Health, submitted applications to IncubAlliance and AI House, and have a meeting scheduled with WILCO One BioTech for October 2026. The EIC Accelerator and BPI i-Lab are future targets. The venture is on a clear timeline to incorporation and first pilot within 12 months. The risk is that I am a solo founder, which increases execution risk. I mitigate this by maintaining a network of advisors from Paris-Saclay and Institut Pasteur, and by targeting accelerators like AI NATION that provide structured mentorship. I am open to co-founder recruitment if the programme identifies a suitable candidate. CHECKLIST - [ ] Complete online application form on AI NATION Accelerator website - [ ] Upload motivation letter (this document) - [ ] Upload short essay on innovation and technological differentiation - [ ] Upload short essay on market potential and scalability - [ ] Upload short essay on founding team and feasibility - [ ] Prepare one-page pitch deck in PDF format - [ ] Prepare 90-second video pitch (if required by programme) - [ ] Verify eligibility: confirm that pre-revenue, pre-incorporation startups are accepted - [ ] Confirm programme dates and location requirements for Germany residency - [ ] Gather reference or recommendation letter from Paris-Saclay or Institut Pasteur contact EDITOR NOTES - Eligibility risk: The programme is in Germany. The venture targets France. Confirm whether the accelerator requires the founder to be based in Germany during the programme, or whether remote participation is allowed. If physical presence is required, the founder must be willing to relocate temporarily. - Fact verification: The AUROC 0.804 on Platinum benchmark is stated as published SOTA. Verify that mCSM-lig AUROC 0.70 is the correct comparator on the same benchmark and that no newer structure-free method has surpassed 0.804 since the profile was written. - Gap: The profile does not specify whether the founder has a co-founder or any team members. The application should clarify whether the founder is open to recruiting a co-founder through the accelerator, or whether the solo founder status is a deliberate choice. - Gap: The profile mentions partnerships with Servier, Sanofi, and Paris-Saclay but does not specify whether any formal agreement or letter of support exists. The application should include at least one letter of support from a named partner if possible. - Gap: The EUR 10,000 amount is small. The application should explicitly state how the funds will be spent and why this amount is sufficient for the next milestone, to avoid the perception that the venture needs significantly more capital.